Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Visionary Ventures
Deal Size : $11.9 million
Deal Type : Series A Financing
Re-vana Therapeutics Raises $11.9 Million In Series A Financing
Details : The proceeds will advance the development of Re-Vana’s novel and proprietary photo-crosslinked EyeLief®, EyeLief-SD™ and OcuLief® biodegradable drug delivery technologies and will enable expansion of the company’s operations and development teams...
Brand Name : Undislosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
December 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Visionary Ventures
Deal Size : $11.9 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?